CN102266444A - A drug for treating allergic purpura - Google Patents
A drug for treating allergic purpura Download PDFInfo
- Publication number
- CN102266444A CN102266444A CN2011102011280A CN201110201128A CN102266444A CN 102266444 A CN102266444 A CN 102266444A CN 2011102011280 A CN2011102011280 A CN 2011102011280A CN 201110201128 A CN201110201128 A CN 201110201128A CN 102266444 A CN102266444 A CN 102266444A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- purpura
- examples
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 title claims abstract description 21
- 208000031814 IgA Vasculitis Diseases 0.000 title claims abstract description 21
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 title claims abstract description 21
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 title claims abstract description 5
- 229940079593 drug Drugs 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 240000001606 Adenanthera pavonina Species 0.000 claims 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 claims 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 claims 1
- 244000043158 Lens esculenta Species 0.000 claims 1
- 241000207929 Scutellaria Species 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 244000141331 Amomum villosum Species 0.000 abstract 1
- 241000596154 Belamcanda Species 0.000 abstract 1
- 241000222435 Lentinula Species 0.000 abstract 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract 1
- 240000001910 Momordica cochinchinensis Species 0.000 abstract 1
- 241000750718 Pterocarpus santalinus Species 0.000 abstract 1
- 210000000232 gallbladder Anatomy 0.000 abstract 1
- 206010037549 Purpura Diseases 0.000 description 21
- 241001672981 Purpura Species 0.000 description 21
- 238000011282 treatment Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 230000008034 disappearance Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010000087 Abdominal pain upper Diseases 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010001580 Albuminuria Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000036555 skin type Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000002562 urinalysis Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 241001346334 Amomum tsao-ko Species 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000620028 Dolichoris Species 0.000 description 2
- 206010060820 Joint injury Diseases 0.000 description 2
- 235000009815 Momordica Nutrition 0.000 description 2
- 241000218984 Momordica Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000022182 gross hematuria Diseases 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229950006142 carbazochrome salicylate Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CELKBRMLNUNCIP-HTFHIHPASA-M sodium;2-hydroxybenzoate;[(e)-(3-hydroxy-1-methyl-6-oxo-2,3-dihydroindol-5-ylidene)amino]urea Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.NC(=O)N\N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 CELKBRMLNUNCIP-HTFHIHPASA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- QXKXDIKCIPXUPL-UHFFFAOYSA-N sulfanylidenemercury Chemical group [Hg]=S QXKXDIKCIPXUPL-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种治疗过敏性紫癜的药物，其成分配伍(按重量份计)为：木鳖子25份，地锦草35g，红花50份，熊胆25份，草果25份，射干35份，紫檀香38份，扁豆花40份。该药物主治过敏性紫癜，治愈率可达95％以上，总有效率98％。The invention relates to a medicine for treating allergic purpura, and the composition (by weight) is: 25 parts of Momordica cochinchinensis, 35g of Herba Euphorbiae, 50 parts of Carthamus tinctorius, 25 parts of Bear Gallbladder, 25 parts of Amomum villosum, 35 parts of Belamcanda chinensis, 38 parts of Pterocarpus santalinus, and 40 parts of Lentinula odoratum. The medicine is mainly used to treat allergic purpura, and the cure rate can reach more than 95%, and the total effective rate is 98%.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of anaphylactoid purpura, especially, relate to a kind of Mongolian medicine for the treatment of anaphylactoid purpura.
Background technology
Anaphylactoid purpura be by anaphylactogen cause disease whole body skin that the little blood vessel wall generation of person immune inflammation causes go out purpura, purpura can cause arthralgia swelling, stomachache have blood in stool and urinate in anaphylactic diseases such as albumen, blood appear.Also claim Allergic purpura (being called for short AP).This disease is along with various air, water source, food pollution and inappropriate medication etc. have increase trend at present.This is sick owing to add up a plurality of organs and organize protracted course of disease to have caused the multiple burden of health, psychology and economic dispatch for vast patient, has a strong impact on patient's physical and mental health.This sick child child, juvenile prevalence height see that from present clinical development trend the trend that becomes frequently-occurring disease should draw attention.
Modern medicine is treated this sick first-selected desensitizer, antihistaminic medicine, glucocorticoid medicine and immunosuppressant treatment at present.For example, Claritin: hismanal, chlorphenamine, calcium gluconate; Reduce the vascular permeability medicine: carbazochrome salicylate, rutin, vitamin C; Anticoagulant medicine: persantin; Adrenocortical hormone: hydrocortisone, prednisone (prednisone), dexamethasone; For kidney type or prednisone treatment gastrointestinal disease patient, also adopt immunosuppressant (as chemotherapeutics such as cyclophosphamide, azathioprines).But these methods treatment times is long, toxic and side effects is big, therapeutic effect is undesirable.
Also have the hemostasis of use Flos Carthami eight-medicine powder to treat in existing Mongolian medicine's treatment, but Herba indigoferae Pseudotinctoriae is a Vermilion in this powder, this medicine is a heavy metal, and its main component is cinnabar (HgS).Can certain infringement be arranged to gastrointestinal tract and hepatic and renal function as taking this medicine for a long time.From the disease characteristics of anaphylactoid purpura, this sickly complexion is easily involved internal organs such as gastrointestinal tract Liver and kidney, so the Vermilion among the former side is unfavorable to this disease, so this prescription exists bigger side effect and treatment risk.
Summary of the invention
Anaphylactoid purpura Mongolian medicine is called " purpura mass formed by blood stasis ".Be to make intravital three disorders of people because exopathogen is invaded human body.That is: its duty is not taken charge of in the mutual disorder of " conspicuous complying with " " association's day " " Ba Dagan "." association day " heat drop is in blood vessels, CUN KOU is opened and caused that purpura appears in whole skin." association day " heat is attacked gastrointestinal mucosa and is caused that then stomachache has blood in stool; Invade kidney then hematuria and albuminuria, lumbago and edema; The invasion and attack joint causes arthralgia, limitation of activity; Also can accumulate a plurality of internal organs such as skin, gastrointestinal, kidney, joint simultaneously and form the mixed type purpura.
The Mongolian medicine mainly carries out symptomatic treatment to regulate three lock arteries and veins " association day " heat that purifies the blood.The inventor improves original prescription, and deleterious medicinal ingredient Vermilion is replaced with other medicinal ingredients, can promote digestive functions after the replacement, and this cooler side heat of balance has avoided Vermilion to the side effect that GI irritation causes, is that prescription is more reasonable; Simultaneously the compatibility dose is readjusted, use amount is more reasonable.Can obtain more effectively therapeutic effect after the improvement.
Therefore, an object of the present invention is to provide a kind of medicine for the treatment of anaphylactoid purpura, its components compatibility (by weight) is: 25 parts of Semen Momordicaes, Herba Euphorbiae Humifusae 35g, 50 parts on Flos Carthami, 25 parts of Fel Ursis, 25 parts of Fructus Tsaokos, 35 parts of Rhizoma Belamcandae, 38 parts of Lignum pterocarpi indici, 40 parts of Flos dolichoris.Compatibility of drugs dosage need not to float.
This medicine property of medicine is cold, and function heat clearing away, removing heat from blood, lock arteries and veins, hemostasis, adjusting voxel cure mainly various hemorrhages.This Drug therapy is the main treatment anaphylactoid purpura, and cure rate can reach more than 95%, total effective rate 98%.
Another object of the present invention has provided a kind of preparation method of described medicine, it is characterized in that the single medicine of above eight flavors is ground into fine powder in proportion behind the compatibility to break into the watered pill and get final product.Described watered pill makes instructions of taking more convenient with respect to traditional powder.
The clinical practice proof is evident in efficacy with Drug therapy anaphylactoid purpura of the present invention, and toxic and side effects is little, is difficult for recurrence, no drug dependence after the drug withdrawal.This medicine is a pure natural medical, dosage 3g-6g/ days, can cooperate to take with other mongolian medicine to form serial medication.、
Medicine of the present invention clinical practice had ten surplus year.We treat 20,000 many cases patients with anaphylactoid purpura every year in the outpatient service ward at present.Its total effective rate has reached more than 98%, and cure rate reaches more than 95%.And toxic and side effects is little, and relapse rate is low, and is economical convenient.Compare with former side: its former side is a powder, and it is bad that the patient takes mouthfeel.Especially the patient in anaphylactoid purpura patient 6-10 year is in the majority.The children taking mouthfeel of getting up is bad, relatively difficulty.Medicine of the present invention breaks into pill with powder, taking convenience, and mouthfeel is good.Efficiently solve the bad shortcoming of child patient oral powder mouthfeel.Its two, contain heavy metal medicine Vermilion (composition HgS) in the former dosage form and take for a long time gastrointestinal tract is had stimulation, and the purpura renal patient more should not take for a long time.Replace Vermilion with Fructus Tsaoko, solved the problem of above side effect.Can also regulate the effect of taste, promote interior absorption of body of whole dosage form.Make medicine of the present invention be fit to take for a long time.Its three, medicine of the present invention has reduced half with former side's invasion by pathogenic cold medicine of a cold nature Fel Ursi, croceous consumption.Having reduced cold and cool medicine stimulates gastrointestinal.Also significantly reduced the expense of prescription finished product.And do not subtract the therapeutical effect of medicine.Effectively reduced patient's financial burden.Every dose of 3g of present former side, 102 yuan every dose.40 yuan of the every 12g of medicine of the present invention.Average 10 yuan every dose.Be former side's 1/10th.Though medicine of the present invention has reduced price, do not reduce therapeutical effect.The advantage place of Here it is medicine of the present invention.
The specific embodiment
Embodiment 1
Prepare raw material by following weight proportion: 25 parts of Semen Momordicaes, Herba Euphorbiae Humifusae 35g, 50 parts on Flos Carthami, 25 parts of Fel Ursis, 25 parts of Fructus Tsaokos, 35 parts of Rhizoma Belamcandae, 38 parts of Lignum pterocarpi indici, 40 parts of Flos dolichoris, the conventional method by this area is ground into fine powder with raw material then, breaks into the watered pill afterwards promptly.
Embodiment 2 (test of pesticide effectiveness data)
Medicine of the present invention is to the influence (capillary glass-tube method) of normal clotting time of mice
[purpose]
Desire is understood the influence of medicine of the present invention to normal clotting time of mice, thereby further studies the mechanism of action of this medicine treatment anaphylactoid purpura.
[material]
Animal: Kunming white mouse, secondary cleaning, ♂, body weight 20 ± 2g is purchased by University of the Inner Mongol Animal Experimental Study center, the quality certification number: 8806M35.Equipment: glass capillary (internal diameter 1mm, long 10cm, Huhehaote City's scientific and technological development institute product, the metering quality certification number: 92 amount machine words the 003rd), stopwatch (Shanghai) etc.Reagent: by reagent-medicine of the present invention, normal saline, purified water (heavily steaming self-control).
[method]
1. by the preparation of reagent: accurately take by weighing medicine of the present invention (giving coarse pulverization earlier) 5.0g, be made into 3% suspension by 30 times of clinical consumption (3g/50kg body weight people consumption per day), bottled standby.
2. get 20 of white mice, by two groups of body weight random stratified compatibilities, i.e. processed group and matched group, 10 every group, the labelling of weighing.Adapt to 24h post processing group and press the administration volume gastric infusion of 0.2ml/10g body weight, 1 time/day, at 9 o'clock in the morning is to administration between 9 thirty, totally 5 days.Matched group is given and is waited the capacity normal saline.The two treated animals water inlet of taking food naturally during the administration, all the other are identical.Insert mice eyes ball rear vein beard with capillary glass tube behind the last administration 1h and get blood.Pick up counting in the autoblood inflow pipe, blood is filled with the back and is taken out glass capillary, lie on the desk, the about 0.5cm in capillary tube two ends that fractureed every 15～20 seconds also slowly draws back to the left and right, whether the observation place of fractureing has the blood clotting silk, till the appearance of blood clotting silk, between lasting, institute is clotting time, and the meansigma methods of glass capillary two end datas is the blood clotting time of this white mice.
[result]
Medicine of the present invention can obviously shorten the clotting time of its normal white mice, and Blood clotting is promptly arranged.This hemostatic mechanism remains further to be studied.
[discussion]
This result of the test has verified that medicine of the present invention has hemostasia effect.This medicine Blood clotting and treatment anaphylactoid purpura have internal relation, need further research to illustrate.
Table 1: experimental animal body weight table (g)
Table 2: to the influence (test data (second)) of normal clotting time of mice
Embodiment 3
Clinical trial
Materials and methods
1.1 material
1.1.1 case is selected
The anaphylactoid purpura infant of selecting in JIUYUE, the 2005-2006 year Decembers Mongolian medicine of Mongolian medicine hospital Hematology hospitalization in Inner Mongolia Autonomous Region is totally 191 examples, be divided into observation group and matched group at random, wherein male 93 examples, women 98 examples, be first attack or recurrence for the first time, and meet diagnostic criteria person.
1.1.2 diagnostic criteria
Meet " practical paidonosology " the 7th edition diagnostic criteria in 2002 (being the new diagnostic criteria of anaphylactoid purpura of nineteen ninety American Rheumatism Association's formulation) of Zhu Futang chief editor, national institution of higher education's state-compiled textbook sixth version " internal medicine " diagnostic criteria that various diagnosis is edited with reference to Ye Rengao, Lu Zaiying simultaneously.
1.1.3 clinical material
Observation group: male 45 examples, women 50 examples, totally 95 examples, age 3-14 year, average (9.81 ± 2.75) year, the preceding course of disease of being admitted to hospital (6.39 ± 4.43) day, 68 examples of falling ill first, 27 examples of falling ill for the second time; 84 examples have the skin purpura in the 95 routine infants, and digestive tract is impaired 45 examples, accounts for 47.37%; Just positive 23 examples of occulting blood account for 24.21%; Joint injury 31 examples are arranged, account for 32.63%; Kidney is impaired 34 examples, accounts for 35.79%, and wherein gross hematuria has 10 examples, microscopic hematuria 24 examples, albuminuria 33 examples.Clinical classification situation: skin-type 16 examples, joint type 13 examples, abdomen type 20 examples, kidney type 34 examples, mixed type 26 examples.
Matched group: male 48 examples, women 48 examples, totally 96 examples, age 3-14 year, average (9.08 ± 2.55) year, the preceding course of disease of being admitted to hospital (7.03 ± 4.38) day, 70 examples of falling ill first, 26 examples of falling ill for the second time; 89 examples have the skin purpura in the 96 routine infants, and digestive tract is impaired 47 examples, accounts for 48.96%; Just positive 22 examples of occulting blood account for 22.92%; Joint injury 33 examples are arranged, account for 34.38%; Kidney is impaired 32 examples, accounts for 33.33%, and wherein gross hematuria has 9 examples, microscopic hematuria 23 examples, albuminuria 30 examples.Clinical classification situation: skin-type 20 examples, joint type 12 examples, abdomen type 16 examples, kidney type 32 examples, mixed type 32 examples.
1.1.4 two groups of basic conditions
Basic condition when table 3 a liang group infant is admitted to hospital
Two groups of patient's sexes, age, the course of disease, Clinical typing etc. all do not have significant difference P＞0.05, have comparability.
Method
1.2.1 the side's of treatment medicine and method
Matched group gives conventional western medicines such as vitamin C, calcium preparation, cimetidine, chlorphenamine, hydrocortisone by the routine clinical Therapeutic Method of doctor trained in Western medicine.Observation group uses medicine of the present invention when giving conventional Western medicine, every day 1-2 time, and each 5-15 grain (being equivalent to 1.0-3g), 14 days is a course of treatment; Observing the treatment time limit is 2 courses of treatment of renal purpura, and other are various to be a course of treatment.Follow Mongolian medicine's Coryza Treated by Syndrome Differentiation principle simultaneously, according to different situations abdomen type compatibility Bart day-7 of pathological changes symptom, joint type compatibility Gu Gule-11, treatments such as kidney type compatibility Sa Ri loud, high-pitched sound day enlightening, Ulan-3 soup, Su Gemu happy-10.
1.2.2 observational technique:
Do all cases the next day once just conventional in the therapeutic process, do routine urinalysis in 3 days one time, examine the record skin purpura situation of taking off that disappears when doing a routine blood test week, symptom of digestive tract disappearance situation, joint transference cure situation, hematuria, albuminuria disappearance situation; Produce effects after 1-2 course of treatment, effective, invalid total routine number and various purpura produce effects, effective, invalid routine number; The routine number of kidney damage and skin purpura routine number repeatedly etc. appear in the therapeutic process.
1.2.3 statistical method
Measurement data is added up with X2 check or definite probabilistic method with the T method of inspection or the approximate T method of inspection, enumeration data.
1.2.4 efficacy assessment standard
All evaluation is all unified with reference to Zhang Zhinan chief editor " hematopathy diagnosis and criterion of therapeutical effect " in case treatment back.Produce effects: resolution of symptoms such as skin purpura, arthralgia, stomachache, routine urinalysis is normal.Effectively: symptoms such as skin purpura major part disappears, arthralgia, stomachache disappear substantially, and routine urinalysis is the result obviously improve.Invalid: the skin purpura occurs repeatedly, and symptoms such as arthralgia, stomachache are for disappearing, and routine urinalysis does not have improvement.
2 results
2.1 observation group and matched group total effective rate (seeing Table 4)
Table 4 liang group patient total effective rate
Annotate: ※ is for comparing (P＜0.05) with matched group
There were significant differences (P＜0.05) for two groups of total effective rates, and observation group's curative effect is better than matched group.
Two groups of various purpura effective percentage (seeing Table 5)
The table 5 liang various purpura effective percentage of group
Annotate: ※ is for comparing no significant difference (P＞0.05) with matched group, there were significant differences (P＜0.05) in order to compare with matched group for ※ ※.
The effective percentage of two groups of skin-types, joint type, abdomen type, mixed type does not have significant difference (P＞0.05); There were significant differences for the effective percentage of kidney type and total effective rate (P＜0.05), and observation group is better than matched group.
2.3 two groups of patient's cardinal symptoms and fecal occult blood extinction time (seeing Table 6)
The comparison of table 6 liang group patient's cardinal symptom and fecal occult blood extinction time
Annotate: there were significant differences (P＜0.05) in order to compare with matched group for ※, and ※ ※ is for comparing no significant difference with matched group
(P＞0.05)。
Two groups of patient skin purpura regression times, stomachache extinction time, there were significant differences for the fecal occult blood extinction time (P＜0.05), and observation group is shorter than matched group the time.Two groups of patient joint transference cure times do not have significant difference (P＞0.05).This has illustrated that this Therapeutic Method is evident in efficacy to skin-type, purpura abdominalis.
2.4 a situation arises (seeing Table 7) for two groups of patient's renal damages
Table 7 liang group patient renal damage incidence rate relatively
Annotate: ※ is for comparing no significant difference (P＞0.05) with matched group.
Two groups of patient's renal damage incidence rates do not have significant difference (P＞0.05), and this may have relation with weak point observing time, awaits further research.
2.5 two groups of patient's ERY disappearance situations (seeing Table 8)
Table 8 liang group patient ERY disappearance rate relatively
Annotate: there were significant differences (P＜0.05) in order to compare with matched group for ※
There were significant differences (P＜0.05) for two groups of patient's ERY disappearance rate, and observation group is better than matched group.
2.6 two groups of patient's urine protein disappearance situations (seeing Table 9)
Table 9 liang group patient urine protein disappearance rate relatively
Annotate: ※ is for comparing no significant difference (P＞0.05) with matched group
Two groups of patient's urine protein disappearance rate do not have significant difference (P＞0.05), and this may have relation with weak point observing time, awaits further research.
2.7 two groups of patient skin purpuras are situation (seeing Table 10) repeatedly
Table 10 liang group patient skin purpura rate is repeatedly compared
Annotate: there were significant differences (P＜0.05) in order to compare with matched group for ※, and observation group is starkly lower than matched group.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102011280A CN102266444A (en) | 2011-07-19 | 2011-07-19 | A drug for treating allergic purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102011280A CN102266444A (en) | 2011-07-19 | 2011-07-19 | A drug for treating allergic purpura |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102266444A true CN102266444A (en) | 2011-12-07 |
Family
ID=45049025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102011280A Pending CN102266444A (en) | 2011-07-19 | 2011-07-19 | A drug for treating allergic purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102266444A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108261479A (en) * | 2018-01-16 | 2018-07-10 | 内蒙古医科大学 | A kind of Mongolian medicine prescription for treating immunologic thrombocytopenic purpura |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785810A (en) * | 2010-01-26 | 2010-07-28 | 张云平 | Traditional Chinese medicine preparation for anaphylactoid purpura treatment |
-
2011
- 2011-07-19 CN CN2011102011280A patent/CN102266444A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785810A (en) * | 2010-01-26 | 2010-07-28 | 张云平 | Traditional Chinese medicine preparation for anaphylactoid purpura treatment |
Non-Patent Citations (2)
| Title |
|---|
| 《中国民族医药杂志》 20100430 韩咏梅等 新古日古木-8胶囊剂挥发油提取和包合工艺研究 第54-55页 1-2 , 第4期 * |
| 《北方药学》 20100430 董志强等 新古日古木-8胶囊剂成型工艺的研究 第21-23页 1-2 第7卷, 第2期 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108261479A (en) * | 2018-01-16 | 2018-07-10 | 内蒙古医科大学 | A kind of Mongolian medicine prescription for treating immunologic thrombocytopenic purpura |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101780254B (en) | Traditional Chinese medicine compound for treating intestinal tumor | |
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| Man et al. | A randomized, double-blind, placebo-controlled trial of a Chinese herbal Sophora flower formula in patients with symptomatic haemorrhoids: a preliminary study | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN102727628B (en) | Chinese medicinal composition for treating functional constipation through hilum therapy | |
| CN106620604A (en) | Navel moxibustion traditional Chinese medicine composition for treating chronic diarrhea as well as preparation method and application thereof | |
| CN102266444A (en) | A drug for treating allergic purpura | |
| CN105267300A (en) | Acne removing traditional Chinese medicine composition | |
| CN102125671A (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN104147544A (en) | Traditional Chinese medicinal composition for treating chronic anal cryptitis | |
| CN116173164A (en) | Traditional Chinese medicine composition for treating liver cancer and postoperative radiotherapy and chemotherapy and preparation method thereof | |
| CN103550702A (en) | Traditional Chinese medicine composition for cerebral arterial thrombosis | |
| CN108653680A (en) | A kind of navel paster for treating menorrhalgia of cold-stagnation and blood-stasis type | |
| CN101862376B (en) | Medicament for treating oviduct obstructive infertility and preparation method thereof | |
| CN105412822A (en) | Spleen-strengthening blood stasis-removing Chinese herbal compound composition and application thereof | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104524458A (en) | Traditional Chinese medicinal powder for treating hepatic calculus and preparation method of powder | |
| CN104055943A (en) | Medicament for treating ulcerative colitis | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN106728819A (en) | A kind of medicine and preparation method for treating chronic dermatitis | |
| CN106377572A (en) | Application of folium cylocaryae paliuri or extract and composition thereof to preparation of health food or medicine for preventing and/or relieving stomach-heat syndrome | |
| CN105853940A (en) | Traditional Chinese medicine for treating bile disease | |
| CN121059745A (en) | A Mongolian medicine composition for treating chronic kidney disease and its application | |
| CN106177382A (en) | The treatment pharmaceutical composition of oral ulcer, its preparation method and preparation | |
| CN103566306B (en) | A kind of Chinese medicine for the treatment of apoplexy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111207 |